Longitudinal growth in height, weight and subcutaneous skinfolds was evaluated in 20 girls and 11 boys aged 0.8 to 15.8 years, from the time of transplantation onwards. Diagnosis at onset of follow up were: Biliary atresia(BA) (8 children), Autoimmune Cirrhosis (AC) (7), Fulminant Hepatic Failure(FHF) (9), Cryptogenetic Cirrhosis (CC) (3), miscelaneous (M) (4) Anthropometric measurements were carried out in a standardized way every 6 months. Immunosuppression therapy consisted of prednisone, cyclosphorine, and azathioprime the first month, followed by cyclosporine and steroids, together with a series of other measures as a part of the transplantation program. Children were followed for variable periods from 0.42 to 3.55 years. At the moment of transplant, height deficit was different in each diagnosis group mean initial height was -1.14 SD in BA, -1.39 SD in Ac, -0.57 SD in CC, and-0.34 in FHF. In the Miscellaneous heterogeneous group (4 children with Alagille syndrome, Byler disease, Alpha-1 Antytripsin and Glucogenosis) mean height was -2.86 SD. During follow up growth in each group also differed: those with BA showed significant net gain in height (1.18cm, SD 0.24, p<0.005). Neither children with AC, CC, or M showed any significant gain in height after liver transplant. In those cases with available anthropometric measurements, some children showed catch-up growth in height BEFORE transplant, probably due to the therapeutic measures taken as part of the transplant program. Children with FHF did not modify their growth after transplant because it was not altered before the transplant. Catch up growth in transplanted children with BA are similar to those found in other centers with experience in liver transplant. Long term physical growth is an adequate indicator of response to the liver transplant program, including quality of medical care, biological variables, therapeutic indications and the whole set of other measures composing the transplant program.